Mydecine Innovations Group Inc C.MYCO

Alternate Symbol(s): MYCOF

Healthcare Advertising Agencies

Mydecine Innovations Group Inc. is a Canada-based biotechnology company. The Company is engaged in developing medications and therapies to address mental health disorders, such as nicotine addiction and posttraumatic stress disorder (PTSD). The Company conducts research and development on second generation compounds in Canada with a focus on developing and commercializing psychedelic-inspired regulated medicines. The Company has two lead 3,4-Methylenedioxymethamphetamine (MDMA) candidates. The Company is channeling its MYCO-005, MYCO-006, and MYCO-007 families of patent-pending second-generation MDMA and Psilocybin analogs through Applied Pharmaceutical Innovation (API). It utilizes artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them accessible to the general public upon Health Canada and Food and Drug Administration (FDA) approval.

CSE:MYCO - Post by User

Mydecine Innovations Group Inc

Bullboard Posts

Comment by Earnanickelon Feb 10, 2017 12:19am

127 Views

Post# 25826620

RE:Very concerned about NF being delisted

I would be more concerned about VP being delisted than NF, mainly because VP was removed from the CSE composite and NF was added to it. VP's days are actually numbered until it's possibly delisted from the CSE. At the same time I don't believe anyone should hold VP of NF as a long term investment, they are just good day to day money makers for us little folk.

Bullboard Posts

The investment impact of the U.S. 25% tariff on Canadian imports